Mohammad Kazzem Gheybi1, Shokrollah Farrokhi2, Mohammad Reza Ravanbod3, Afshin Ostovar4, Valiollah Mehrzad5, Pardis Nematollahi6. 1. Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran. kazzem7@yahoo.com. 2. Department of Immunology, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran. 3. Department of Hematology and Oncology, Bushehr University of Medical Sciences, Bushehr, Iran. 4. Department of Epidemiology, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran. 5. Department of Hematology and Oncology, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Department of Cancer Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Abstract
BACKGROUND: T regulatory cells (Tregs) are known to negatively control immune response. The frequency of these cells was inversely correlated with clinical outcomes of breast cancer. CD19+CD24hiCD38hi cells also play a critical role in inflammation and autoimmune disease. However, their function in tumor immune response is less studied. In this study we aimed to determine the role of CD19+CD24hiCD38hi cells and some other clinicopathological variables in increasing the proportion of Tregs in breast cancer patients. METHODS: We selected 47 patients with invasive ductal breast carcinoma and 50 healthy controls and obtained their blood samples. RESULTS: The proportion of circulating CD4+CD25+Foxp3+ Tregs and CD19+CD24hiCD38hi cells was significantly increased in breast cancer patients. We also found that increased proportion of Tregs in breast cancer is correlated with HER2 amplification, advanced clinical stages, serum TGF-β1 and increased CD19+CD24hiCD38hi cells in the peripheral blood. CONCLUSION: Altogether, our data suggest that as much as Tregs, CD19+CD24hiCD38hi B cells could also have a part in the suppression of immune response in breast cancer.
BACKGROUND: T regulatory cells (Tregs) are known to negatively control immune response. The frequency of these cells was inversely correlated with clinical outcomes of breast cancer. CD19+CD24hiCD38hi cells also play a critical role in inflammation and autoimmune disease. However, their function in tumor immune response is less studied. In this study we aimed to determine the role of CD19+CD24hiCD38hi cells and some other clinicopathological variables in increasing the proportion of Tregs in breast cancerpatients. METHODS: We selected 47 patients with invasive ductal breast carcinoma and 50 healthy controls and obtained their blood samples. RESULTS: The proportion of circulating CD4+CD25+Foxp3+ Tregs and CD19+CD24hiCD38hi cells was significantly increased in breast cancerpatients. We also found that increased proportion of Tregs in breast cancer is correlated with HER2 amplification, advanced clinical stages, serum TGF-β1 and increased CD19+CD24hiCD38hi cells in the peripheral blood. CONCLUSION: Altogether, our data suggest that as much as Tregs, CD19+CD24hiCD38hi B cells could also have a part in the suppression of immune response in breast cancer.
Entities:
Keywords:
Breast cancer; CD19 + CD24 + CD38 + B cells; Clinicopathological variables; T regulatory cells